The success of Sildenafil initially fueled a surge for pharma, nevertheless recent shifts present a uncertain outlook for those considering a stake. Off-patent competitors are eroding revenue, and continued legal https://craigijvs173383.arwebo.com/63703585/the-blue-pill-and-pharma-a-precarious-investment